Company: INDP
Filing Date: 2025-03-13
Form Type: POS AM
Source: 0001493152-25-010137
Chunk: 19

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: POS AM
Chunk 19
---
 |
| ● | our                                                                                                                               
 ability to develop, manufacture and commercialize our product candidates;                                                         |
| ● | the                                                                                                                               
 risk of product liability claims, the availability of reimbursement, the influence of extensive and costly government regulation; |
| ● | our                                                                                                                               
 estimates regarding future revenue, expenses capital requirements and the need for additional financing;                          |
| ● | our                                                                                                                               
 ability to maintain the listing of our shares of common stock on Nasdaq; and                                                      |
| ● | our                                                                                                                               
 ability to continue as a going concern.                                                                                           |

As more fully described under the heading “Risk Factors” and elsewhere in this prospectus and under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024, many important factors affect our ability to achieve our stated objectives and to develop and commercialize any product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks and uncertainties set forth in our filings with the SEC. You should read this prospectus and any free writing prospectuses that we have authorized for use in this offering, and any information incorporated by reference herein with the understanding that our actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

| 10 |

<div align='center'>USE OF PROCEEDS</div>

This prospectus relates to our shares of common stock that may be offered and sold from time to time by YA. All of our shares offered by the selling stockholder pursuant to this prospectus will be sold by the selling stockholder for its own account. We will not receive any of the proceeds from these sales.

We may receive up to $20.0 million aggregate gross proceeds under the Purchase Agreement from any sales of shares of our common stock we make to YA pursuant to the Purchase Agreement. However, we are unable to estimate the actual amount of proceeds that we may receive, as it will depend on the number of shares that we choose to sell, our